NCT02909556已完成不适用
ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic Stenosis
Symetis SA17 个研究点 分布在 3 个国家目标入组 120 人开始时间: 2016年12月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 17
- 主要终点
- Rate of all-cause mortality at 30 days follow-up
研究概览
简要总结
Clinical trial aimed at evaluating the safety and performance of the ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System for CE mark approval purposes.
详细描述
Single arm, prospecitve, multicenter, non-randomized and open trial. The purpose of this trial is to collect and safety and performance data concerning the ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System
The ACURATE neo™ AS Aortic Bioprosthesis and ACURATE neo™ AS TF Transfemoral Delivery System are intended for use in minimally invasive, transcatheter aortic valve replacement (TAVR) using transfemoral access in patients presenting with severe aortic valve stenosis.
The primary objective is to evaluate the safety and performance of the study device in patients presenting with severe aortic stenosis (AS) considered to be high risk for surgery.
The secondary objective is to evaluate adverse events and study device performance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient 75 years of age and older
- •Severe aortic stenosis defined as:
- •Mean aortic gradient > 40 mmHg or
- •Peak jet velocity > 4.0 m/s or
- •Aortic valve area of < 1.0 cm2
- •High risk candidate for conventional AVR defined as:
- •Logistic EuroSCORE 1 ≥ 20% or
- •STS Score ≥ 8% or
- •Heart team (cardiologist and cardiac surgeon) consensus that patient is not a surgical candidate for conventional AVR due to significant co-morbid conditions unrelated to aortic stenosis
- •NYHA Functional Class > II
- •Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT
- •Patient willing to participate in the study and provides signed informed consent
排除标准
- •Congenital aortic stenosis or unicuspid or bicuspid aortic valve
- •Non-stenotic Aortic Insufficiency
- •Severe eccentricity of calcification
- •Severe mitral regurgitation (>2+)
- •Presence of mitral bioprosthesis
- •Presence of previously implanted aortic bioprosthesis
- •Presence of prosthetic ring
- •Anatomy NOT appropriate for transfemoral implant due to the size, disease and degree of calcification or tortuosity of the aorta or ilio-femoral arteries
- •Thoracic (TAA) or abdominal (AAA) aortic aneurysm
- •Presence of endovascular stent graft for treatment of TAA or AAA
- •Trans-oesophageal echocardiogram (TEE) is contraindicated
- •Evidence of intra-cardiac mass, thrombus or vegetation
- •Severe ventricular dysfunction with ejection fraction < 20%
- •Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month prior to implant procedure
- •Acute Myocardial Infarction within 1 month prior to implant procedure
- •Previous TIA or stroke within 3 months prior to implant procedure
- •Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant procedure
- •Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit
- •Severe coagulation conditions
- •Refusal of blood transfusions
- •Systolic pressure <80mmHg, cardiogenic shock, need for inotropic support or IABP
- •Hypertrophic cardiomyopathy with or without obstruction
- •Active bacterial endocarditis or other active infections
- •Hepatic failure (> Child B)
- •Chronic renal dysfunction with serum creatinine > 2.5 mg/dL or renal dialysis
- •Refusal of surgery
- •Severe COPD requiring home oxygen
- •Neurological disease severely affecting ambulation or daily functioning, or dementia
- •Life expectancy < 12 months due to non-cardiac co-morbid conditions
- •Inability to tolerate anticoagulation therapy
- •Contraindication to contrast media or allergy to nickel
- •Currently participating in an investigational drug or another device study
- •Non-valvular aortic stenosis
- •Non-calcific acquired aortic stenosis
结局指标
主要结局
Rate of all-cause mortality at 30 days follow-up
时间窗: 30 days post-implant
次要结局
- Rate of clinical events as defined per VARC guidelines(7 days, 30 days, 12 months post-implant)
- Procedural success(Day of implant)
- Device success(Day of implant)
- VARC Composite Safety at 30 days(30 days)
- Clinical improvement from baseline as per NYHA Functional Classification(7 days, 30 days, 12 months post-implant)
- Improvement from baseline in hemodynamic function: effective orifice area, mean transprosthetic gradient(7 days, 30 days, 12 months)
- Total aortic regurgitation(7 days, 30 days, 12 months)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
不适用
ACURATE Neo™ TA Delivery System in Patient With Severe Aortic StenosisAortic StenosisNCT02950428Symetis SA60
已完成
不适用
ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic StenosisAortic StenosisNCT02986737Symetis SA15
已完成
不适用
ACURATE™ Transapical Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2010-01)Aortic Symptomatic StenosisNCT03143673Symetis SA50
已完成
不适用
Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation IIAortic Valve StenosisNCT03192813Ceric Sàrl796
已完成
不适用
Symetis ACURATE Neo™ Valve Implantation SAVI TF RegistryAortic StenosisNCT02306226Symetis SA1,000